Advertisement

Assessing Canonical and Adaptive Natural Killer Cell Function in Suppression Assays In Vitro

  • Dhifaf SarhanEmail author
  • Jeffrey S. Miller
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1913)

Abstract

The in vitro culture system outlined in this chapter allows for standardized protocols to examine canonical and adaptive natural killer (NK) cell responses while interacting with immune suppressor cells such as regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSC). These interactions pathologically occur during tumorigenesis and tumor progression. Strategies to study the effects of ex vivo purified immune suppressor cells from cancer patients on the function of NK cell antitumor activity will help to understand suppressive mechanisms to improve immunotherapy. Immune checkpoint inhibitors have recently demonstrated tremendous clinical responses in patients with diverse types of cancers. However, their effect on NK cell function is not very well studied. Here, we have adapted a coculture system that previously has been utilized to study regulatory T cells. This approach can further be utilized to study the effects of immune checkpoint inhibitors in vitro and ex vivo. We focus on the differences between canonical NK cells and the newly identified subset of NK cells termed “adaptive NK cells.” These cells are induced by cytomegalovirus (CMV) in CMV-seropositive individuals.

Key words

Human canonical and adaptive NK cells Immune suppression Treg MDSC 

Notes

Acknowledgments

This work was funded in part with federal funds from the National Cancer Institute (NCI), NIH, CA111412, and CA65493.

References

  1. 1.
    Caligiuri MA (2008) Human natural killer cells. Blood 112(3):461–469.  https://doi.org/10.1182/blood-2007-09-077438CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Lanier LL (2008) Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 9(5):495–502.  https://doi.org/10.1038/ni1581CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of natural killer cells. Nat Immunol 9(5):503–510.  https://doi.org/10.1038/ni1582CrossRefPubMedGoogle Scholar
  4. 4.
    Raulet DH (2004) Interplay of natural killer cells and their receptors with the adaptive immune response. Nat Immunol 5(10):996–1002.  https://doi.org/10.1038/ni1114CrossRefPubMedGoogle Scholar
  5. 5.
    Vitale M, Cantoni C, Pietra G, Mingari MC, Moretta L (2014) Effect of tumor cells and tumor microenvironment on NK-cell function. Eur J Immunol 44(6):1582–1592.  https://doi.org/10.1002/eji.201344272CrossRefPubMedGoogle Scholar
  6. 6.
    Lopez-Soto A, Gonzalez S, Smyth MJ, Galluzzi L (2017) Control of metastasis by NK cells. Cancer Cell 32(2):135–154.  https://doi.org/10.1016/j.ccell.2017.06.009CrossRefPubMedGoogle Scholar
  7. 7.
    Benson DM Jr, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, Greenfield CN, Porcu P, Devine SM, Rotem-Yehudar R, Lozanski G, Byrd JC, Caligiuri MA (2010) The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116(13):2286–2294.  https://doi.org/10.1182/blood-2010-02-271874CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A, Levine Z, Beiman M, Dassa L, Achdout H, Stern-Ginossar N, Tsukerman P, Jonjic S, Mandelboim O (2009) The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A 106(42):17858–17863.  https://doi.org/10.1073/pnas.0903474106CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Hasmim M, Messai Y, Ziani L, Thiery J, Bouhris JH, Noman MZ, Chouaib S (2015) Critical role of tumor microenvironment in shaping NK cell functions: implication of hypoxic stress. Front Immunol 6.  https://doi.org/10.3389/fimmu.2015.00482
  10. 10.
    O'Sullivan TE, Sun JC (2015) Generation of natural killer cell memory during viral infection. J Innate Immun 7(6):557–562.  https://doi.org/10.1159/000375494CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Lopez-Verges S, Milush JM, Schwartz BS, Pando MJ, Jarjoura J, York VA, Houchins JP, Miller S, Kang SM, Norris PJ, Nixon DF, Lanier LL (2011) Expansion of a unique CD57(+)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci U S A 108(36):14725–14732.  https://doi.org/10.1073/pnas.1110900108CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Schlums H, Cichocki F, Tesi B, Theorell J, Beziat V, Holmes TD, Han H, Chiang SC, Foley B, Mattsson K, Larsson S, Schaffer M, Malmberg KJ, Ljunggren HG, Miller JS, Bryceson YT (2015) Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity 42(3):443–456.  https://doi.org/10.1016/j.immuni.2015.02.008CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Sun JC, Beilke JN, Lanier LL (2009) Adaptive immune features of natural killer cells. Nature 457(7229):557–561.  https://doi.org/10.1038/nature07665CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Paust S, Gill HS, Wang BZ, Flynn MP, Moseman EA, Senman B, Szczepanik M, Telenti A, Askenase PW, Compans RW, von Andrian UH (2010) Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat Immunol 11(12):1127–1135.  https://doi.org/10.1038/ni.1953CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    O'Sullivan TE, Sun JC, Lanier LL (2015) Natural killer cell memory. Immunity 43(4):634–645.  https://doi.org/10.1016/j.immuni.2015.09.013CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Schlums H, Jung M, Han HY, Theorell J, Bigley V, Chiang SCC, Allan DSJ, Davidson-Moncada JK, Dickinson RE, Holmes TD, Hsu AP, Townsley D, Winkler T, Wang WX, Aukrust P, Nordoy I, Calvo KR, Holland SM, Collin M, Dunbar CE, Bryceson YT (2017) Adaptive NK cells can persist in patients with GATA2 mutation depleted of stem and progenitor cells. Blood 129(14):1927–1939.  https://doi.org/10.1182/blood-2016-08734236CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Tsai FY, Keller G, Kuo FC, Weiss M, Chen J, Rosenblatt M, Alt FW, Orkin SH (1994) An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature 371(6494):221–226.  https://doi.org/10.1038/371221a0CrossRefPubMedGoogle Scholar
  18. 18.
    Tesi B, Davidsson J, Voss M, Rahikkala E, Holmes TD, Chiang SCC, Komulainen-Ebrahim J, Gorcenco S, Rundberg Nilsson A, Ripperger T, Kokkonen H, Bryder D, Fioretos T, Henter JI, Mottonen M, Niinimaki R, Nilsson L, Pronk CJ, Puschmann A, Qian H, Uusimaa J, Moilanen J, Tedgard U, Cammenga J, Bryceson YT (2017) Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms. Blood 129(16):2266–2279.  https://doi.org/10.1182/blood-2016-10-743302CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Sarhan D, Cichocki F, Zhang B, Yingst A, Spellman SR, Cooley S, Verneris MR, Blazar BR, Miller JS (2016) Adaptive NK cells with low TIGIT expression are inherently resistant to myeloid-derived suppressor cells. Cancer Res 76(19):5696–5706.  https://doi.org/10.1158/0008-5472.CAN-16-0839CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Cichocki F, Cooley S, Davis Z, DeFor TE, Schlums H, Zhang B, Brunstein CG, Blazar BR, Wagner J, Diamond DJ, Verneris MR, Bryceson YT, Weisdorf DJ, Miller JS (2016) CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT. Leukemia 30(2):456–463.  https://doi.org/10.1038/leu.2015.260CrossRefPubMedGoogle Scholar
  21. 21.
    Nagel JE, Collins GD, Adler WH (1981) Spontaneous or natural-killer cyto-toxicity of K562 erythroleukemic cells in normal-patients. Cancer Res 41(6):2284–2288PubMedGoogle Scholar
  22. 22.
    Brunner KT, Mauel J, Cerottini JC, Chapuis B (1968) Quantitative assay of lytic action of immune lymphoid cells on 51cr-labelled allogeneic target cells in vitro—inhibition by isoantibody and by drugs. Immunology 14(2):181–196PubMedPubMedCentralGoogle Scholar
  23. 23.
    Mao Y, Sarhan D, Steven A, Seliger B, Kiessling R, Lundqvist A (2014) Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Clin Cancer Res 20(15):4096–4106.  https://doi.org/10.1158/1078-0432.CCR-14-0635CrossRefPubMedGoogle Scholar
  24. 24.
    Lechner MG, Liebertz DJ, Epstein AL (2010) Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 185(4):2273–2284.  https://doi.org/10.4049/jimmunol.1000901CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Hippen KL, Merkel SC, Schirm DK, Nelson C, Tennis NC, Riley JL, June CH, Miller JS, Wagner JE, Blazar BR (2011) Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease. Am J Transplant 11(6):1148–1157.  https://doi.org/10.1111/j.1600-6143.2011.03558.xCrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Hippen KL, Merkel SC, Schirm DK, Sieben CM, Sumstad D, Kadidlo DM, McKenna DH, Bromberg JS, Levine BL, Riley JL, June CH, Scheinberg P, Douek DC, Miller JS, Wagner JE, Blazar BR (2011) Massive ex vivo expansion of human natural regulatory T cells (T-regs) with minimal loss of in vivo functional activity. Sci Transl Med 3(83).  https://doi.org/10.1126/scitranslmed.3001809CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Microbiology, Tumor and Cell Biology, Karolinska InstitutetKarolinska University HospitalStockholmSweden
  2. 2.Division of Hematology, Oncology and Transplantation, Department of MedicineUniversity of Minnesota Masonic Cancer CenterMinneapolisUSA

Personalised recommendations